New shot aims to shrink painful, swollen livers

NCT ID NCT05281328

Ongoing Disease control Sponsor: Camurus AB Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new injectable medication called CAM2029 can safely reduce liver size and ease symptoms in people with polycystic liver disease. About 71 adults with symptoms like abdominal pain, bloating, and shortness of breath will receive either the real treatment or a placebo for 53 weeks. The goal is to see if the treatment shrinks the liver and improves patients' quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Bon Secours Richmond Community Hospital

Richmond, Virginia, 23602, United States
Hannover Medical School

Hanover, 30625, Germany
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mount Sinai Hospital

New York, New York, 10029, United States
Radboud UMC, Department of Gastroenterology and Hepatology

Nijmegen, 6525 GA, Netherlands
The New York Presbyterian Hospital

New York, New York, 10065, United States
Universitaetsklinikum Müenster

Münster, 48149, Germany
University Hospitals KU Leuven

Leuven, B-3000, Belgium
University of Texas Southwestern Medical Center

Dallas, Texas, 75380, United States
Universitätsklinikum Leipzig

Leipzig, 04103, Germany

Conditions

Explore the condition pages connected to this study.

POLYCYSTIC LIVER DISEASE